Systemic Reactions to Allergen Immunotherapy Amd Skin Testing (chackos)
|ClinicalTrials.gov Identifier: NCT00594802|
Recruitment Status : Completed
First Posted : January 16, 2008
Last Update Posted : August 9, 2010
Allergy skin tests and allergen immunotherapy are common procedures for both the diagnosis and treatment of atopic diseases. Allergen immunotherapy has proved to be effective in reducing the symptoms of allergic rhinitis and asthma1-2. Despite its clinical benefit, there is risk of systemic reactions associated with these procedures.
The systemic reaction rate to skin testing for aeroallergens is significant lower than the rate of reactions to immunotherapy, but it is not negligible. Lin et al reported only 2 patients who had systemic allergic reactions to skin testing for respiratory allergies in 10,400 patients tested.3 They determined the overall risk of inducing anaphylactic reactions by skin testing to be less than 0.02% and other studies have produced similar results.4-5 The rate of systemic reactions to skin testing is likely underscored. Thompson et. al reported a systemic reaction rate of 6% of patients receiving skin testing.6 It is important to recognize the risk of systemic reactions seeing skin testing is commonly done. It is also imperative to recognize the treatments for these reactions to prevent progression.
Hypothesis The systemic reaction rate to allergen immunotherapy and skin testing to aeroallergens is higher than previously reported. Biphasic anaphylactic reactions rarely occur with allergen immunotherapy and skin testing.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Systemic Reactions to Allergen Immunotherapy Amd Skin Testing|
|Study Start Date :||August 2006|
|Primary Completion Date :||June 2007|
|Study Completion Date :||June 2007|
CHART REVIEW ONLY
CHART REVIEW OF PATIENTS WITH SYSTEMIC REACTIONS
- This is a prospective observational study of patients who are having either skin testing or allergen immunotherapy for the diagnosis or treatment of allergic rhinitis, conjunctivitis, and/or asthma.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00594802
|United States, Florida|
|Tampa, Florida, United States, 33613|
|Principal Investigator:||RICHARD F LOCKEY, MD||USF DIRECTOR OF ALLERGY AND IMMUNOLOGY|